In this study, we aimed to compare BCL-2, MCL-1 and BCL-xL as therapeutic targets in AML and to investigate the molecular mechanisms of selective inhibitors targeting these related antiapoptotic proteins. The gene discussed is BCL2; the disease is acute myeloid leukemia.